Fenben Cancer Treatment
Fenben cancer treatment is a controversial new method for treating cancer that has garnered a lot of attention online. The claim is that a veterinary drug called fenbendazole, which is used to treat parasites in animals, can also cure human cancer.
The claim is based on anecdotal evidence that one person who used fenbendazole and other conventional cancer treatments went into remission. While there are some studies that show fenbendazole can slow cancer growth in petri dishes and mice, there is no evidence that it is effective against human cancer. In fact, Health Canada lists fenbendazole as a drug for veterinary use only and does not approve it for treating people.
Fenbendazole is a widely available antiparasitic medication that is used to treat rodent pinworms. It has minimal side effects and is usually tolerated by humans. In a 2021 study published in Scientific Reports, researchers found that the benzimidazole class of drugs that fenbendazole belongs to can inhibit cancer cell growth in a laboratory dish. The scientists also tested the drug on mouse xenografts (cancer cells implanted in animals for testing). The fenbendazole significantly reduced tumor size and prevented cancer cell proliferation.
A separate research group tested the combination of fenbendazole and a compound called RAPA in a lab dish. They found that the fenbendazole and RAPA had synergistic effects against 5-fluorouracil-resistant SNU-C5 colorectal cancer cells. They also found that the drugs caused apoptosis and that they did not require p53 for anticancer activity in these cells.
They then encapsulated the fenbendazole and the RAPA into various polymers and tested the drugs for their ability to suppress the proliferation of the SNU-C5/5-FUR colon cancer cells in a 24-hour assay. They found that the mPEG-b-PCL micelle with a fenbendazole:RAPA molar ratio of 1:1 was the most effective at reducing cancer cell viability.
The research team also analyzed mPEG-b-PCL nanoparticles with different fenbendazole:RAPA ratios to determine the optimal molar ratio of each drug for the most synergistic effect. They found that the mPEG-b-PCL particles with a fenbendazole:RAPA combination of 1:2 showed the most potent anticancer activity.
In a study published in the journal Scientific Reports, the scientists who were originally working on the fenbendazole:RAPA combinations examined their cytotoxic and cytostatic effects against human prostate cancer cells in vitro. They also studied the cells in a mouse xenograft model of prostate cancer. The fenbendazole and RAPA combination caused less proliferation of the cancer cells in the xenografts, and they observed that the cytostatic effects were more pronounced under conditions of hypoxia, which is common in a human prostate tumor. This is a promising finding, but it’s important to remember that this is only an animal experiment. There is no evidence that fenbendazole can cure cancer in humans and it has not passed any rigorous clinical trials. In addition, there are other factors that could have contributed to Joe Tippens’ remission, such as his other conventional cancer treatments, which aren’t being accounted for.fenben cancer treatment